Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001

Solid Tumor Clinical Trial

Official title:

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL001 in Patients With Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06410092
• Other study ID #: FTL001-101
• Status: Recruiting
• Phase: Phase 1
• Start date: June 5, 2023
• Est. completion date: March 2027

Study information

• Verified date: May 2024
• Source: Sound Biopharmaceuticals Ltd.
• Contact: CMO
• Phone: 0086-28-85250987
• Email: wenshb[@]soundbiopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced and metastatic solid tumors.

Description:

The study is divided into two phases, Part 1 (FTL001 dose escalation) and Part 2 (FTL001 dose expansion), and is intended to include approximately 26-44 participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: March 2027
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients must give informed consent to this study prior to the study and sign a written informed consent form voluntarily;

2. Age =18 and =75, both male and female;

3. Expected survival time of more than 3 months;

4. Histologically or cytologically confirmed advanced solid tumors;

5. Patients with advanced recurrence, metastasis and refractory solid tumors whose disease progresses after standard treatment or who are intolerant to standard treatment or have no standard treatment (the definitions of standard treatment and refractory recurrence refer to authoritative diagnosis and treatment guidelines at home and abroad);

6. At least 1 measurable lesion at baseline according to the definition of RECISTv1.1;

7. ECOG performance score of 0 or 1;

8. Adequate organ function;

9. Fertile men or women with the possibility of becoming pregnant, using an effective contraceptive method during the trial, and continuing contraception for 6 months after the end of treatment;

Exclusion Criteria:

1. Have a history of malignancies other than the disease studied within the previous 5 years, except for malignancies that have been cured after treatment and have no risk of recurrence (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);

2. Prior anticancer therapy (chemotherapy, targeted agents, radiotherapy, and immunotherapy) within 28 days before first dose;

3. Prior treatment with any anti-CD137 antibody or drug (single agent or combination);

4. Adverse reactions caused by previous treatment that did not recover to CTCAE (version 5.0) grade 1 or below, hair loss, neurotoxicity to CTCAE (version 5.0) grade 2 or below, or other adverse reactions that researchers judged to have no safety risk could be included;

5. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;

6. Active primary or metastatic tumors of the central nervous system (except in patients who have previously been treated and discontinued treatment 4 weeks before the first study drug administration, symptomless patients who do not require long-term glucocorticoid therapy), seizures, spinal cord compression, or carcinomatous meningitis;

7. Have or have suspected active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc., but the following conditions can be included: Type 1 diabetes that can be controlled by alternative therapy alone, skin diseases that do not require systemic treatment (e.g. Psoriasis, vitiligo);

8. Suffering from clinical symptoms or symptomatic treatment of pleural fluid or ascites;

9. Severe cardiovascular and cerebrovascular diseases, such as uncontrolled or poorly controlled high blood pressure or Pulmonary hypertension; Unstable angina pectoris or myocardial infarction, coronary artery bypass grafting or stenting within 6 months prior to study administration; Chronic heart failure with heart function =2 (NYHA rating); Degree II and above heart block; Left ventricular ejection fraction (LVEF) < 50%; Study cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to medication;

10. History of pulmonary disease: interstitial pneumonia, obstructive pulmonary disease and symptomatic bronchospasm;

11. Active infection requiring intravenous anti-infective treatment, or unhealed wounds or ulcers occurring within 14 days prior to initial administration;

12. Test positive for human immunodeficiency virus (HIV) antibodies;

13. Hepatitis (non-alcoholic steatohepatitis, alcoholic or drug-related, autoimmune hepatitis) and cirrhosis with portal hypertension; Active hepatitis B or C:

14. Active tuberculosis (TB) is known to exist. Subjects suspected of active TB should be examined for chest X-rays, sputum, and clinical signs and symptoms.

15. Received systemic corticosteroids (prednisone > 10 mg/ day or equivalent) or other immunosuppressive drugs within 14 days prior to the initial study;

16. Receive live vaccination within 4 weeks prior to the initial study administration;

17. Major surgical procedures within 4 weeks prior to initial study medication (as defined by the investigator, open biopsy, severe trauma, etc.). Note: It is acceptable to replace an intravenous drip dropper. Had a major surgical procedure planned within 30 days of initial dosing (as determined by the investigator). Local procedures (such as placement of systemic ports, air-core needle biopsies, and prostate biopsies) are permitted, provided that the procedure is completed at least 24 hours before the first administration of the investigational therapeutic agent;

18. Pregnant or lactating women;

19. History of hypersensitivity or idiosyncrasy to the excipients of the study drug or to any monoclonal antibody;

20. Those who have previously received cellular immunotherapy (CAR-T).

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• FTL001
IV infusion every 2 weeks

Locations

Country	Name	City	State
China	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing
China	West China Hospital	Chengdu	Sichuan
China	Chongqing University Cancer Hospital	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Sound Biopharmaceuticals Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with dose-limiting toxicities (DLTs)	Number of participants with DLTs during the 28 days following the first administration of FTL001	First Cycle (28 days)
Secondary	To preliminarily evaluate the anti-tumor activity	Computed tomography (CT) scans of tumors will be evaluated according to RECIST 1.1 and iRECIST (2017).	every 2 cycles (each cycle is 28 days)
Secondary	Pharmacokinetic (PK) measure: Maximum observed serum concentration (Cmax)	PK samples will be collected at predefined timepoints to determine Cmax.	From first dose (Cycle 1 Day 1, each cycle is 28 days) until the last dose (up to 2 years)
Secondary	Pharmacokinetic (PK) measure: Area under the plasma concentration versus time curve (AUC)	PK samples will be collected at predefined timepoints to determine AUC.	From first dose (Cycle 1 Day 1, each cycle is 28 days) until the last dose (up to 2 years)